版本:
中国

BRIEF-Sophiris Bio says first patient has been dosed in phase 2b study of topsalysin

June 8 Sophiris Bio Inc

* Sophiris Bio announces that the first patient has been dosed in phase 2b study of topsalysin in patients with clinically significant localized prostate cancer Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐